Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Psoriasis Research Institute of Guangzhou
Guangzhou, Guangdong, Chinahistpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The institute has developed TC Cream, the world's first botanical small-molecule drug for psoriasis vulgaris. Phase IIb results (NCT03372811) demonstrated superior efficacy over vehicle control with excellent safety profile. Currently conducting multicenter Phase III trials in the U.S. through FDA IND clearance[1][2][5].
- Therapeutic areas
- Dermatology
- Modalities
- Botanical small molecules(TC Cream)
- Industry
- Biotech
02
Partnerships
SUNY Downstate Medical Center (clinical trial site)[5]NCT03372811 clinical trial network sites
Beyond the preview
Go deeper on Psoriasis Research Institute of Guangzhou.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psoriasis Research Institute of Guangzhou.